Microwave & magnetic (M2) proteomics reveals CNS-specific protein expression waves that precede clinical symptoms of experimental autoimmune encephalomyelitis

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Raphael, Itay ^a   Mahesula, Swetha ^a   Purkar, Anjali ^a   Black, David ^a   Catala, Alexis ^a   Gelfond, Jonathon A L ^b   Forsthuber, Thomas G ^a   Haskins, William E ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME; SPECTRIN; SYNAPSIN;

ANIMAL; C57BL MOUSE; CENTRAL NERVOUS SYSTEM; DISEASE MODEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; MAGNETISM; METABOLISM; MICROWAVE RADIATION; MOUSE; MULTIPLE SCLEROSIS; PROCEDURES; PROTEOMICS;

ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MAGNETIC PHENOMENA; MICE; MICE, INBRED C57BL; MICROWAVES; MULTIPLE SCLEROSIS; PROTEOME; PROTEOMICS; SPECTRIN; SYNAPSINS;

EID: 84906922870     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06210     Document Type: Article

References (83)

1. Mateen, F. J. et al. Neurological disorders in the 11th revision of the International Classification of Diseases: now open to public feedback. Lancet Neurol 11, 484-485, doi:10.1016/S1474-4422(12)70125-4 (2012).
2. Steinman, L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85, 299-302 (1996).
3. Goverman, J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9, 393-407, doi:10.1038/nri2550 (2009).
4. Rovaris, M. et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5, 343-354, doi:10.1016/S1474- 4422(06)70410-0 (2006).
5. Dhib-Jalbut, S. et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 176, 198-215 (2006).
6. Hartung, H. P. et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 40, 197-210 (1992).
7. Benveniste, E. N. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med (Berl) 75, 165-173 (1997).
8. Veldhoen, M. The role of T helper subsets in autoimmunity and allergy. Curr Opin Immunol 21, 606-611, doi:10.1016/j.coi.2009.07.009 (2009).
9. Olsson, T. Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol 40, 211-218 (1992).
10. Sospedra, M. & Martin, R. Immunology of multiple sclerosis. Annu Rev Immunol 23, 683-747, doi:10.1146/annurev.immunol.23.021704.115707 (2005). (Pubitemid 40563183)
11. Noseworthy, J. H., Lucchinetti, C., Rodriguez, M. & Weinshenker, B. G. Multiple sclerosis. N Engl J Med 343, 938-952, doi:10.1056/ NEJM200009283431307 (2000).
12. Thompson, A. J. et al. Primary progressive multiple sclerosis. Brain: a journal of neurology 120 (Pt 6), 1085-1096 (1997).
13. Lublin, F. D. & Reingold, S. C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46, 907-911 (1996).
14. Confavreux, C., Vukusic, S., Moreau, T. & Adeleine, P. Relapses and progression of disability in multiple sclerosis. NEJM 343, 1430-1438, doi:10.1056/NEJM200011163432001 (2000).
15. Poonawalla, A. H. et al. Composite MRI scores improve correlation with EDSS in multiple sclerosis. Mult Scler 16, 1117-1125, doi:10.1177/ 1352458510374892 (2010).
16. Bakshi, R. et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7, 615-625, doi:10.1016/S1474-4422(08)70137-6 (2008).
17. Tourdias, T. & Dousset, V. Neuroinflammatory Imaging Biomarkers: Relevance to Multiple Sclerosis and its Therapy. Neurotherapeutics, doi:10.1007/s13311-012-0155-4 (2012).
18. Filippi, M. & Agosta, F. Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging 31, 770-788, doi:10.1002/jmri.22102 (2010).
19. Neema, M., Stankiewicz, J., Arora, A., Guss, Z. D. & Bakshi, R. MRI in multiple sclerosis: what's inside the toolbox? Neurotherapeutics 4, 602-617, doi:10.1016/j.nurt.2007.08.001 (2007). (Pubitemid 47505349)
20. Rifai, N., Gillette, M. A. & Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24, 971-983 (2006).
21. Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1, 845-867 (2002).
22. Raphael, I. et al. Microwave and magnetic (M(2)) proteomics of the experimental autoimmune encephalomyelitis animal model of multiple sclerosis. Electrophoresis 33, 3810-3819, doi:10.1002/elps.201200200 (2012).
23. Mahesula, S. et al. Immunoenrichment microwave and magnetic proteomics for quantifying CD47 in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Electrophoresis 33, 3820-3829, doi:10.1002/elps.201200515 (2012).
24. Ottens, A. K. et al. Neuroproteomics in neurotrauma. Mass Spec Rev 25, 380-408, doi:10.1002/mas.20073 (2006).
25. Ottens, A. K. et al. A multidimensional differential proteomic platform using dual-phase ion-exchange chromatography-polyacrylamide gel electrophoresis/ reversed-phase liquid chromatography tandem mass spectrometry. Anal Chem 77, 4836-4845, doi:10.1021/ac050478r (2005). (Pubitemid 41076674)
26. Haskins, W. E. et al. Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry. J Neurotrauma 22, 629-644, doi:10.1089/neu.2005.22.629 (2005). (Pubitemid 40840379)
27. Wang, K. K. et al. Proteomics studies of traumatic brain injury. Intl Rev Neurobiology 61, 215-240, doi:10.1016/S0074-7742(04)61009-9 (2004). (Pubitemid 39752437)
28. Kushnir, M. M. et al. Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin Chem 59, 982-990, doi:10.1373/clinchem. 2012.195594 (2013).
29. Lehmann, S. et al. Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clin Chem Lab Med: CCLM/FESCC 51, 919-935, doi:10.1515/cclm-2012-0723 (2013).
30. Robinson, W. H., Utz, P. J. & Steinman, L. Genomic and proteomic analysis of multiple sclerosis. Opinion. Curr Opin Immunol 15, 660-667 (2003).
31. Shen, P. et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507, 366-370, doi:10.1038/nature12979 (2014).
32. Sriskantharajah, S. et al. Regulation of experimental autoimmune encephalomyelitis by TPL-2 kinase. J Immunol 192, 3518-3529, doi:10.4049/jimmunol.1300172 (2014).
33. Sosa, R. A., Murphey, C., Ji, N., Cardona, A. E. & Forsthuber, T. G. The kinetics of myelin antigen uptake by myeloid cells in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 191, 5848-5857, doi:10.4049/jimmunol.1300771 (2013).
34. Peterson, J. W., Bo, L., Mork, S., Chang, A. & Trapp, B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurology 50, 389-400 (2001).
35. Klaver, R., De Vries, H. E., Schenk, G. J. & Geurts, J. J. Grey matter damage in multiple sclerosis: a pathology perspective. Prion 7, 66-75, doi:10.4161/pri.23499 (2013).
36. Lassmann, H. The pathology of multiple sclerosis and its evolution. Phil Trans R Soc B 354, 1635-1640, doi:10.1098/rstb.1999.0508 (1999). (Pubitemid 29534430)
37. Encinas, J. A. et al. Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice. J Immunol 157, 2186-2192 (1996).
38. Bahmanyar, S., Moreau-Dubois, M. C., Brown, P., Cathala, F. & Gajdusek, D. C. Serum antibodies to neurofilament antigens in patients with neurological and other diseases and in healthy controls. J Neuroimmunol 5, 191-196 (1983).
39. Hu, J. et al. Optimized proteomic analysis of a mouse model of cerebellar dysfunction using amine-specific isobaric tags. Proteomics 6, 4321-4334, doi:10.1002/pmic.200600026 (2006). (Pubitemid 44277034)
40. Farias, A. S., Pradella, F., Schmitt, A., Santos, L. M. & Martins-de-Souza, D. Ten years of proteomics in multiple sclerosis. Proteomics 14, 467-480, doi:10.1002/pmic.201300268 (2014).
41. Han, M. H. et al. Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. J Exp Med 209, 1325-1334, doi:10.1084/jem. 20101974 (2012).
42. Fallarino, F. et al. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med 16, 897-902, doi:10.1038/nm.2183 (2010).
43. Spindler, K. R. & Hsu, T. H. Viral disruption of the blood-brain barrier. Trends Microbiol 20, 282-290, doi:10.1016/j.tim.2012.03.009 (2012).
44. Petrucci, T. C. & Morrow, J. S. Synapsin I: an actin-bundling protein under phosphorylation control. J Cell Biol 105, 1355-1363 (1987).
45. Baines, A. J. & Bennett, V. Synapsin I is a microtubule-bundling protein. Nature 319, 145-147, doi:10.1038/319145a0 (1986). (Pubitemid 16189730)
46. Sikorski, A. F., Terlecki, G., Zagon, I. S. & Goodman, S. R. Synapsin I-mediated interaction of brain spectrin with synaptic vesicles. J Cell Biol 114, 313-318 (1991).
47. Nichols, R. A., Sihra, T. S., Czernik, A. J., Nairn, A. C. & Greengard, P. Calcium/calmodulin-dependent protein kinase II increases glutamate and noradrenaline release from synaptosomes. Nature 343, 647-651, doi:10.1038/343647a0 (1990).
48. Choi, D. W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1, 623-634 (1988).
49. Choi, D. W. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett 58, 293-297 (1985).
50. Centonze, D. et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 29, 3442-3452, doi:10.1523/JNEUROSCI.5804-08.2009 (2009).
51. Marchesi, V. T. & Steers, E., Jr. Selective solubilization of a protein component of the red cell membrane. Science 159, 203-204 (1968).
52. Repasky, E. A., Granger, B. L. & Lazarides, E. Widespread occurrence of avian spectrin in nonerythroid cells. Cell 29, 821-833 (1982).
53. Speicher, D. W. & Marchesi, V. T. Erythrocyte spectrin is comprised of many homologous triple helical segments. Nature 311, 177-180 (1984).
54. Goodman, S. R. et al. Brain spectrin: of mice and men. Brain research bulletin 36, 593-606 (1995).
55. Stankewich, M. C. et al. A widely expressed betaIII spectrin associated with Golgi and cytoplasmic vesicles. Proc Natl Acad Sci U.S.A. 95, 14158-14163 (1998).
56. Berghs, S. et al. betaIV spectrin, a new spectrin localized at axon initial segments and nodes of ranvier in the central and peripheral nervous system. J Cell Biol 151, 985-1002 (2000).
57. Stabach, P. R. & Morrow, J. S. Identification and characterization of beta V spectrin, a mammalian ortholog of Drosophila beta H spectrin. J Biol Chem 275, 21385-21395, doi:10.1074/jbc.C000159200 (2000). (Pubitemid 30481839)
58. Goodman, S. R. et al. A spectrin-like protein from mouse brain membranes: immunological and structural correlations with erythrocyte spectrin. Cell Mot 3, 635-647 (1983).
59. Goodman, S. R. et al. A spectrin-like protein from mouse brain membranes: phosphorylation of the 235,000-dalton subunit. Am J Phys 247, C61-73 (1984).
60. Goodman, S. R., Lopresti, L. L., Riederer, B. M., Sikorski, A. & Zagon, I. S. Brain spectrin(240/235A): a novel astrocyte specific spectrin isoform. Brain Res Bulletin 23, 311-316 (1989).
61. Goodman, S. R., Zagon, I. S., Coleman, D. B. & McLaughlin, P. J. Spectrin expression in neuroblastoma cells. Brain Res Bulletin 16, 597-602 (1986).
62. Zagon, I. S., McLaughlin, P. J. & Goodman, S. R. Localization of spectrin in mammalian brain. J Neurosci 4, 3089-3100 (1984).
63. Clark, M. B. et al. Brain alpha erythroid spectrin: identification, compartmentalization, and beta spectrin associations. Brain Res 663, 223-236 (1994).
64. DeBello, W. M., Betz, H. & Augustine, G. J. Synaptotagmin and neurotransmitter release. Cell 74, 947-950 (1993).
65. Riederer, B. M., Zagon, I. S. & Goodman, S. R. Brain spectrin(240/235) and brain spectrin(240/235E): two distinct spectrin subtypes with different locations within mammalian neural cells. J Cell Biol 102, 2088-2097 (1986).
66. Riederer, B. M., Lopresti, L. L., Krebs, K. E., Zagon, I. S. & Goodman, S. R. Brain spectrin(240/235) and brain spectrin(240/235E): conservation of structure and location within mammalian neural tissue. Brain Res Bull 21, 607-616 (1988).
67. Zagon, I. S., Higbee, R., Riederer, B. M. & Goodman, S. R. Spectrin subtypes in mammalian brain: an immunoelectron microscopic study. J Neurosci 6, 2977-2986 (1986).
68. Wang, K. K. et al. Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem 273, 22490-22497 (1998).
69. Siman, R., Baudry, M. & Lynch, G. Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease. Proc Natl Acad Sci U.S.A. 81, 3572-3576 (1984).
70. Harris, A. S., Croall, D. E. & Morrow, J. S. The calmodulin-binding site in alphafodrin is near the calcium-dependent protease-I cleavage site. J Biol Chem 263, 15754-15761 (1988).
71. Pineda, J. A. et al. Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma 24, 354-366, doi:10.1089/neu.2006.003789 (2007). (Pubitemid 46492156)
72. Cardali, S. & Maugeri, R. Detection of alphaII-spectrin and breakdown products in humans after severe traumatic brain injury. J Neurosurg Sci 50, 25-31 (2006).
73. Hall, E. D. et al. Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: more than a focal brain injury. J Neurotrauma 22, 252-265, doi:10.1089/neu.2005.22.252 (2005). (Pubitemid 40333519)
74. Beer, R. et al. Temporal profile and cell subtype distribution of activated caspase-3 following experimental traumatic brain injury. J Neurochem 75, 1264-1273 (2000).
75. Weiss, E. S. et al. Alpha II-spectrin breakdown products serve as novel markers of brain injury severity in a canine model of hypothermic circulatory arrest. Ann Thoracic Surg 88, 543-550, doi:10.1016/j.athoracsur.2009.04.016 (2009).
76. Jaros, J. A., Guest, P. C., Bahn, S. & Martins-de-Souza, D. Affinity depletion of plasma and serum for mass spectrometry-based proteome analysis. Meth Molecular Biol 1002, 1-11, doi:10.1007/978-1-62703-360-2-1 (2013).
77. Koutroukides, T. A. et al. Characterization of the human serum depletome by label-free shotgun proteomics. J Sep Sci 34, 1621-1626, doi:10.1002/ jssc.201100060 (2011).
78. Munoz, J. J. & Mackay, I. R. Production of experimental allergic encephalomyelitis with the aid of pertussigen in mouse strains considered genetically resistant. J Neuroimmunol 7, 91-96 (1984).
79. Nekrasova, T. et al. ERK1-deficientmice show normal T cell effector function and are highly susceptible to experimental autoimmune encephalomyelitis. J Immunol 175, 2374-2380 (2005).
80. Shive, C. L., Hofstetter, H., Arredondo, L., Shaw, C. & Forsthuber, T. G. The enhanced antigen-specific production of cytokines induced by pertussis toxin is due to clonal expansion of T cells and not to altered effector functions of longterm memory cells. Eur J Immunol 30, 2422-2431, doi:10.1002/1521-4141(2000)30:8&60;2422::AID-IMMU2422&62;3.0.CO;2-H (2000).
81. Heeger, P. S. et al. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J Immunol 164, 5771-5781 (2000).
82. Hofstetter, H. H. & Forsthuber, T. G. Kinetics of IL-17- and interferon-gamma-producing PLPp-specific CD4 T cells in EAE induced by coinjection of PLPp/IFA with pertussis toxin in SJL mice. Neurosci Lett 476, 150-155, doi:10.1016/j.neulet.2010.04.018 (2010).
83. Sing, T., Sander, O., Beerenwinkel, N. & Lengauer, T. ROCR: visualizing classifier performance in R. Bioinformatics 21, 3940-3941, doi:10.1093/bioinformatics/bti623 (2005). (Pubitemid 41535515)